The Portable Ophthalmic Ultrasound Device segmentation by application separates the market into diagnostic, screening, therapeutic and research use cases. Diagnostic devices dominate, accounting for roughly 55 % of total revenue, because they are integral to posterior segment evaluation, retinal detachment detection, and intra‑ocular tumor assessment in ophthalmic clinics and hospitals. Screening applications, representing about 25 % of the market, are driven by community‑based cataract and glaucoma programs that require rapid, non‑invasive imaging in outreach settings. Therapeutic use, contributing an estimated 15 % of sales, supports intra‑operative guidance for procedures such as vitrectomy and laser therapy, where real‑time imaging improves precision and outcomes. Finally, research activities—prototype validation, drug‑delivery studies, and academic investigations—compose the remaining 5 % of the market, reflecting limited but high‑value purchases by universities and R&D labs. Collectively, these application segments define the demand profile and guide manufacturers’ product‑development priorities across the portable ophthalmic ultrasound landscape. The weight of each segment is reflected in manufacturers’ revenue mix, with diagnostic units driving the bulk of unit shipments and pricing power, while screening devices have lower per‑unit cost but higher volume in emerging markets.
